| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 08/11/2009 | US7572813 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents; N-[2-[[(cis) -2-[[1- (4-Chlorophenyl)ethyl]amino]cyclohexyl]amino]-2-oxoethyl]-3-(trifluoromethyl)benzamide |
| 08/11/2009 | US7572799 Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors |
| 08/11/2009 | US7572796 excitatory amino acid antagonists for treating neurodegenerative diseases as cerebrovascular diseases, epilepsy, schizophrenia, Alzheimer's disease, Parkinson's disease, Huntington's disease, cerebral ischaemia, infarction, psychoses; 6-{3-[4-(4-fluorobenzyl)-1-piperidyl]propyl}-1H-indole-3-carbonitrile |
| 08/11/2009 | US7572793 Tau protein kinase 1 inhibitors; treatment for neurodegenerative disorders; Alzheimer's Disease, Parkinson's disease, Pick's Disease, vision defects; antiischemic, antidiabetic, anticarcinogenic, antitumor agents, antidepressants |
| 08/11/2009 | US7572787 Substituted naphthalene sulfonamides |
| 08/11/2009 | US7572786 Substituted 1-piperidin-3-yl-4-piperidin-4-yl-piperazine derivatives and their use as neurokinin antagonists |
| 08/11/2009 | US7572785 Substituted imidazoles as cannabinoid receptor modulators |
| 08/11/2009 | US7572779 Improved oral bioavailability of 17 beta-estradiol by adminstering the lower alkanoate; contraceptives, hormone replacement therapy |
| 08/11/2009 | US7572774 Methods for treating glutamate cytotoxicity with beta-naphthoquinone compounds |
| 08/11/2009 | US7572762 Materials and methods relating to the induction of apoptosis in target cells |
| 08/11/2009 | US7572605 1,2,3,tris(4-hydroxy-butyroyloxy)propane; enhance the uptake of the drug, deliver effective therapeutic doses in a time-delayed fashion, and target specific organs |
| 08/11/2009 | US7572574 Method of measuring neprilysin activity |
| 08/11/2009 | US7572463 Oral dosage forms |
| 08/11/2009 | US7572450 Composition for preventing cell death and/or tissue necrosis resulting from contact with neural thread proteins |
| 08/11/2009 | CA2548834C Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 08/11/2009 | CA2527933C Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| 08/11/2009 | CA2482551C 1-(4-piperidinyl) benzimidazolones as histamine h3 antagonists |
| 08/11/2009 | CA2449402C Substituted tetrahydroisoquinolines for use in the treatment of inflammatory diseases |
| 08/11/2009 | CA2448825C Pharmaceutical compositions of adsorbates of amorphous drug |
| 08/11/2009 | CA2392013C Analgesic compositions containing buprenorphine in combination with naloxone, naltrexone or nalmefene |
| 08/11/2009 | CA2368688C Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 08/11/2009 | CA2362385C Heterodiazinon compound |
| 08/11/2009 | CA2359772C Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 08/11/2009 | CA2335012C Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
| 08/11/2009 | CA2320120C Benzisoxazole derivatives having d4-antagonistic activity |
| 08/11/2009 | CA2287521C Human recombinant beta-interferon with improved solubility |
| 08/06/2009 | WO2009097614A1 Methods of treating multiple sclerosis by administering pulse dose calcitrol |
| 08/06/2009 | WO2009097567A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | WO2009097416A1 Imidazolylalkyl- pyridines as dbh inhibitors |
| 08/06/2009 | WO2009097414A1 Use of imidazolylalkyl-pyridines for the treatment of addictive disorders |
| 08/06/2009 | WO2009097401A1 2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| 08/06/2009 | WO2009097309A1 Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands |
| 08/06/2009 | WO2009097306A1 Substituted pyridazine derivatives which have histamine h3 antagonist activity |
| 08/06/2009 | WO2009097278A1 6-SUBSTITUTED-THIO-2-AMINO-QUINOLINE DERIVATIVES USEFUL AS INHIBITORS OF β-SECRETASE (BACE) |
| 08/06/2009 | WO2009096941A1 Substituted heterocyclic ethers and their use in cns disorders |
| 08/06/2009 | WO2009096817A2 Agent for reducing the degree of acute alcoholic intoxication (inebriation) and the use thereof |
| 08/06/2009 | WO2009096810A1 Method for producing a water-soluble pharmaceutical composition |
| 08/06/2009 | WO2009096807A1 Pharmaceutical formulation comprising dicholine salt of succinic acid |
| 08/06/2009 | WO2009096564A1 Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder |
| 08/06/2009 | WO2009096526A1 Carboxylic acid compound or salt thereof |
| 08/06/2009 | WO2009096505A1 Agent for improving attention and concentration powers |
| 08/06/2009 | WO2009096503A1 Benzyl phenyl glucopyranoside derivative |
| 08/06/2009 | WO2009096445A1 Nerve trunk cell propagation accelerator |
| 08/06/2009 | WO2009096354A1 Fentanyl-containing patch for external use |
| 08/06/2009 | WO2009096349A1 Crystalline cinnamide compounds or salts thereof |
| 08/06/2009 | WO2009095923A2 Corroles for neuroprotection and neurorescue |
| 08/06/2009 | WO2009095789A1 Substituted arylamide diazepinopyrimidone derivatives for the treatment of neurodegenerative diseases caused by abnormal activity of gsk3-beta |
| 08/06/2009 | WO2009095788A1 Substituted arylamide oxazepinopyrimidone derivatives |
| 08/06/2009 | WO2009095787A1 Substituted heteroarylamide oxazepinopyrimidone derivatives |
| 08/06/2009 | WO2009095726A1 Acrylamide derivatives as vanilloid receptor 1 modulators |
| 08/06/2009 | WO2009095684A1 Pulmonary formulations of triptans |
| 08/06/2009 | WO2009095621A1 Galenic form for the oral transmucosal delivery of triptans |
| 08/06/2009 | WO2009095499A1 Use of amidoxime carboxylic acid esters and n-hydroxyguanidine carboxylic acid esters for producing prodrugs |
| 08/06/2009 | WO2009095454A2 Method for the identification of patients in need of therapy having minor cognitive disorders and the treatment of such patients |
| 08/06/2009 | WO2009095438A1 Novel aryl piperazine derivatives useful as modulators of dopamine and serotonin receptors |
| 08/06/2009 | WO2009095431A1 Novel salts of o-desmethyl-venlafaxine |
| 08/06/2009 | WO2009095394A1 Diazepanes as histamine h3 receptor antagonists |
| 08/06/2009 | WO2009095265A1 The use of substances for the treatment of central or peripheral insulin receptor impairment and insulin resistance |
| 08/06/2009 | WO2009095254A1 Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| 08/06/2009 | WO2009095253A1 6-halo-pyrazolo[1, 5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mglur) modulators |
| 08/06/2009 | WO2009094713A1 Diagnosis and treatment of sensory defect |
| 08/06/2009 | WO2009073146A3 Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders |
| 08/06/2009 | WO2009043522A3 Use of a peptide as a therapeutic agent |
| 08/06/2009 | WO2009043463A3 Use of gluten exorphin c : as a therapeutic agent |
| 08/06/2009 | WO2009036149A3 Methods for treatment of degenerative disease associated with apoptosis |
| 08/06/2009 | WO2009033795A3 Use of a obestatin as a therapeutic agent |
| 08/06/2009 | WO2009033793A3 Pentagastrin as a therapeutic agent |
| 08/06/2009 | WO2009033721A3 Use of salusin beta alone or in combination with octreotide as a therapeutic agent |
| 08/06/2009 | WO2009011870A8 Reduction of beta-amyloid levels by treatment with the small molecule differentiation-inducing factor |
| 08/06/2009 | WO2008124081A3 Rapid dissolution of combination products |
| 08/06/2009 | WO2008100450A4 Therapeutic effects of bryostatins, bryologs, and other related substances on ischemia/stroke-induced memory impairment and brain injury |
| 08/06/2009 | US20090198145 Compositions, methods, and systems for rapid induction and maintenance of continuous rem sleep |
| 08/06/2009 | US20090197969 Method of reducing brain cell damage or death |
| 08/06/2009 | US20090197968 Extended-release capsules comprising venlafaxine hydrochloride |
| 08/06/2009 | US20090197965 Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease |
| 08/06/2009 | US20090197961 Diclofenac Formulations and Methods of Use |
| 08/06/2009 | US20090197958 Sustained Release Particulate Oral Dosage Forms of (R) Baclofen and Methods of Treatment |
| 08/06/2009 | US20090197952 Glyceride Esters for the Treatment of Diseases Associated with Reduced Neuronal Metabolism of Glucose |
| 08/06/2009 | US20090197951 Substituted Fullerene Formulations and Their Use in Ameliorating Oxidative Stress Diseases or Inhibiting Cell Death |
| 08/06/2009 | US20090197945 Method for Generating Reference Controls for Pharmacogenomic Testing |
| 08/06/2009 | US20090197940 CHONDROPSIN-CLASS ANTITUMOR V-ATPase INHIBITOR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF |
| 08/06/2009 | US20090197935 Primary amines and derivatives thereof as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto |
| 08/06/2009 | US20090197928 Novel Receptor Antagonists and Their Methods of Use |
| 08/06/2009 | US20090197924 2-amino-2-phenyl-alkanol derivatives, their preparation and pharmaceutical compositions containing them |
| 08/06/2009 | US20090197915 Sigma receptor compounds |
| 08/06/2009 | US20090197905 Quaternary opioid carboxamides |
| 08/06/2009 | US20090197898 Selective subtype alpha 2 adrenergic agents and methods for use thereof |
| 08/06/2009 | US20090197897 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors |
| 08/06/2009 | US20090197886 Hexahydro-cycloheptapyrazole cannabinoid modulators |
| 08/06/2009 | US20090197872 Novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their medical use |
| 08/06/2009 | US20090197860 Biaryl substituted diazabicycloalkane derivatives |
| 08/06/2009 | US20090197859 Pyridinyl Amides for the Treatment of CNS and Metabolic Disorders |
| 08/06/2009 | US20090197828 System, method and package for providing a sucrose solution |
| 08/06/2009 | US20090197824 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 08/06/2009 | US20090197823 Aliskiren modulation of neurogenesis |
| 08/06/2009 | US20090197810 Alpha conotoxin peptides with analgesic properties |
| 08/06/2009 | US20090197802 Analogues of GLP-1 |
| 08/06/2009 | US20090197801 Neuritogenic peptides |
| 08/06/2009 | US20090197337 Methods for the production of multimeric proteins and related compositions |
| 08/06/2009 | US20090196935 Pharmaceutical Capsules Comprising Extended Release Dipyridamole Pellets |